1,053
Views
6
CrossRef citations to date
0
Altmetric
Editorial

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?

, , , &
Pages 1107-1110 | Received 09 May 2019, Accepted 30 Jul 2019, Published online: 06 Aug 2019
 

Declaration of interest

G Procopio declares receiving honoraria for advisory board from Bayer, Bristol Myers Squibb, Ipsen, Merck, Novartis, and Pfizer. E Verzoni declares receiving honoraria for advisory board from Pfizer, Bristol Myers Squibb, Ipsen, and EUSA pharm. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

One of the reviewers on this paper has received research funding from and consulted for Pfizer, Merck, BMS, and Roche. Other peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

No funding was received for this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.